X4 Pharmaceuticals, with the slogan "Enabling a better future for people with rare immune disorders," is a commercial-stage clinical biopharmaceutical company focused on improving the lives of individuals with rare immune system diseases. The company's flagship product, mavorixafor, has obtained FDA approval under the brand name XOLREMDI™, marking a significant milestone. Currently, X4 Pharmaceuticals is executing a US launch and working on expanding mavorixafor's applications to cater to additional rare disease patient populations. The company is also gearing up to initiate a pivotal, global Phase 3 clinical trial targeting individuals with certain chronic neutropenic disorders.Driven by a deep understanding of CXCR4 and immune system biology, X4 Pharmaceuticals operates from its corporate headquarters in Boston, Massachusetts and its research center of excellence in Vienna, Austria. The company's commitment to a patient-centric approach is evident in its ongoing efforts to advance treatment options for individuals with rare immune disorders.
Founded in 2014, X4 Pharmaceuticals operates in the Biotechnology, Health Care, and Pharmaceutical sectors and secured a significant $115.00M Post-IPO Debt investment from Hercules Capital on 03 August 2023. This latest consolidation of financial support will likely further bolster the company's endeavors to address unmet needs in the rare disease space and drive continued innovation in the field of immune system therapeutics.
Taxonomy:
biopharmaceutical company, clinical trials, rare diseases, immunodeficiency, neutropenic disorders, mavorixafor therapy, CXCR4 antagonist, WHIM syndrome, Phase 3 clinical trial, regulatory approval, public company, drug development, immune system disorders, patient advocacy
Boston, United States
